Literature DB >> 9236917

Large scale and clinical grade purification of syndecan-1+ malignant plasma cells.

R X Sun1, Z Y Lu, J Wijdenes, J Brochier, C Hertog, J F Rossi, B Klein.   

Abstract

For cancer immunotherapy, it is usually necessary to obtain a large number of tumor cells from patients. We have previously reported that syndecan-I is present only on malignant plasma cells in samples from patients with multiple myelomatosis. We report here that this antigen is cleaved by chymopapain. This makes it possible to develop a rapid and clinical grade procedure to purify large numbers of myeloma cells using anti-syndecan-1 mAb, magnetic beads and chymopapain.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9236917     DOI： 10.1016/s0022-1759(97)00056-2

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN： 0022-1759            Impact factor:   2.303


  5 in total

Review 1.  Microarray-based understanding of normal and malignant plasma cells.

Authors:  John De Vos; Dirk Hose; Thierry Rème; Karin Tarte; Jérôme Moreaux; Karéne Mahtouk; Michel Jourdan; Hartmut Goldschmidt; Jean-François Rossi; Friedrich W Cremer; Bernard Klein
Journal:  Immunol Rev       Date:  2006-04       Impact factor: 12.988

2.  Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma.

Authors:  K Mahtouk; F W Cremer; T Rème; M Jourdan; M Baudard; J Moreaux; G Requirand; G Fiol; J De Vos; M Moos; P Quittet; H Goldschmidt; J-F Rossi; D Hose; B Klein
Journal:  Oncogene       Date:  2006-05-29       Impact factor: 9.867

3.  B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro.

Authors:  Zhao-Yang Lu; Maud Condomines; Karin Tarte; Laure Nadal; Marie Claude Delteil; Jean François Rossi; Christophe Ferrand; Bernard Klein
Journal:  Exp Hematol       Date:  2007-03       Impact factor: 3.084

4.  An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis.

Authors:  Karène Mahtouk; Michel Jourdan; John De Vos; Catherine Hertogh; Geneviève Fiol; Eric Jourdan; Jean-François Rossi; Bernard Klein
Journal:  Blood       Date:  2003-10-23       Impact factor: 22.113

5.  Normal and clonal B lineage cells can be distinguished by their differential expression of B cell antigens and adhesion molecules in peripheral blood from multiple myeloma (MM) patients--diagnostic and clinical implications.

Authors:  R Luque; J A Brieva; A Moreno; A Manzanal; L Escribano; J Villarrubia; J L Velasco; J López-Jiménez; C Cerveró; M J Otero; J Martínez; C Bellas; E Roldán
Journal:  Clin Exp Immunol       Date:  1998-06       Impact factor: 4.330
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.